… ProQR to Participate in Upcoming Investor Conferences LEIDEN, … & CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … 30 days following the presentation date. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Therapeutics Added to NASDAQ Biotechnology Index … & CAMBRIDGE, Mass., Dec. 24, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … and share volume requirements among other criteria. About ProQRProQR Therapeutics is dedicated to changing lives …
Senior leader with extensive global rare disease commercialization experience
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
LEIDEN, Netherlands & CAMBRIDGE, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced that it will
… ProQR to Present at Cowen Health Care Conference LEIDEN, … be accessible from the ‘Investor Relations’ section of ProQR’s website ( www.proqr.com ) under ‘Events and Presentations’. The …
… ProQR Announces Presentations at the OTS Annual Meeting … on QR-110 clinical data in LCA10 David Rodman, MD, EVP of R&D of ProQR, will give a presentation on the recent clinical data …
Preclinical proof of concept data for the AX-0810 program targeting NTCP for cholestatic diseases presented at ASGCT 27th Annual Meeting – Management to host webinar today at 8:00 am EDT to highlight dataMartin Maier, PhD nominated to Board with Annual General